GRAL

Grail Inc

Add to Watchlist

Advanced Chart

80.060

-4.58(-5.411%)1D

Line

Candle

YTD

High

86.190

Open

85.120

VWAP

80.62

Vol

970.33K

Mkt Cap

2.89B

Low

76.950

Amount

78.23M

EV/EBITDA(TTM)

Total Shares

35.97M

2.44B

EV/OCF(TTM)

P/S(TTM)

21.37

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

3 Analyst Rating

-23.98% Downside

Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

-23.98% Downside

Current: 80.060

Low

38.00

Averages

60.86

High

83.71

-23.98% Downside

Current: 80.060

Low

38.00

Averages

60.86

High

83.71

Canaccord

Kyle Mikson

Buy

upgrade

$75 -> $85

2025-10-22

Reason

Canaccord

Kyle Mikson

Price Target

$75 -> $85

2025-10-22

upgrade

Buy

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Grail to $85 from $75 and keeps a Buy rating on the shares. The firm said they remain bullish following relatively positive study results and over $400 million (pending) added to the company's balance sheet, recognizing multiple questions remain regarding the perspective of regulators and clinicians. They also noted that after the market close on Friday, October 17, the company announced the performance and safety results from its registrational PATHFINDER 2 study and saidalthough the data improved from PATHFINDER 1, it is unclear if it will be adequate for FDA approval.

Morgan Stanley

Equal Weight

initiated

$20 -> $38

2025-06-26

Reason

Morgan Stanley

Price Target

$20 -> $38

2025-06-26

initiated

Equal Weight

Reason

Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $38, up from $20. While the firm sees significant long-term potential for Grail's Galleri MCED test, there are also inherent risks associated with novel technologies from a regulatory and reimbursement standpoint, the analyst tells investors. The firm is also updating estimates for Q1 results, noting that its Q2 and 2025 revenue estimates move to $36M and $151M, from prior forecasts of $37M and $149M, respectively.

NINGI Research

downgrade

$14.28

2025-06-09

Reason

NINGI Research

Price Target

$14.28

2025-06-09

downgrade

Reason

Canaccord

Buy

maintain

$32 -> $43

2025-05-14

Reason

Canaccord

Price Target

$32 -> $43

2025-05-14

maintain

Buy

Reason

Canaccord Genuity

Kyle Mikson

Strong Buy

Initiates

$32

2025-04-21

Reason

Canaccord Genuity

Kyle Mikson

Price Target

$32

2025-04-21

Initiates

Strong Buy

Reason

Morgan Stanley

Tejas Savant

Hold

Maintains

$16 → $20

2025-03-18

Reason

Morgan Stanley

Tejas Savant

Price Target

$16 → $20

2025-03-18

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Grail Inc (GRAL.O) is -6.13, compared to its 5-year average forward P/E of -1.73. For a more detailed relative valuation and DCF analysis to assess Grail Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.73

Current PE

-6.13

Overvalued PE

-0.23

Undervalued PE

-3.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.08

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.42

Undervalued EV/EBITDA

-2.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.07

Current PS

84.64

Overvalued PS

19.55

Undervalued PS

-5.42